** Shares of Ajanta Pharma AJPH.NS rise as much as 9.2% to
1,572 rupees, mark their sharpest intraday jump in nearly four
weeks
** The Indian drugmaker posts a 45% jump in March-qtr profit
to 1.29 bln rupees ($17.04 mln), boosted by strong export sales;
rev from ops climbed 32.4% urn:newsml:reuters.com:*:nFWN2D115L
** Branded generic sales in Africa and Asia were up 26% and
46%, respectively, while generic sales in the United States
surged 88%
** (There are) near-term growth concerns but demand outlook
is intact, says BOB Capital Markets and assumes coverage with
"buy" rating and a TP of 1,650
** Positive on AJPH due to strong Abbreviated New Drug
Application pipeline for the U.S. market, launches in branded
generics segment of Asia/Africa/India and better operating
leverage - Motilal Oswal
** The coronavirus-led disruption could be a dampener for
earnings growth in FY21 - Motilal Oswal
** Six of the nine analysts covering the stock have a "buy"
or "strong buy" rating, two "hold", while one rates it at
"strong sell"; median PT is 1,320 rupees - Refinitiv data
** Stock up 47.7% this year, as of last close, outperforming
a 17.6% rise in the Nifty Pharma Index .NIPHARM
($1 = 75.6900 Indian rupees)
(Reporting by Chris Thomas in Bengaluru)
((chris.thomas@thomsonreuters.com; +91-80-6749-8695; Reuters
Messaging: chris.thomas.thomsonreuters.com@reuters.net))